Clinical Trial Update: Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating dabrafenib, trametinib, and hydroxychloroquine in advanced BRAF-mutant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Braf-mutant Melanoma
• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Hydroxychloroquine (hydroxychloroquine)
• Trametinib (trametinib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Advanced BRAF Mutant Melanoma | Phase 1, Phase 2 | Status: COMPLETED